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Abstract
Purpose: Total knee arthroplasty (TKA) is an effective,
but also cost-intensive health care procedure for the
elderly. Furthermore, bearing demographic changes in
Western Europe in mind, TKA-associated financial in-
vestment for health care insurers will increase notably
and thereby catalyze discussions on ressource alloca-
tion to Orthopedic surgery. To derive a quantitative ra-
tionale for such discussions within Western Europe’s
health care systems, a prospective assessment of both
the benefit of TKA from a patient’s perspective as
well as its cost effectiveness from a health care insur-
er’s perspective was implemented.
Methods: A prospective cost effectiveness trial recruit-
ed a total of 65 patients (60% females), who under-
went TKA in 2006; median age of patients was 66
years (interquartile range 61 – 74 years). Before and
three months after surgery patients were interviewed
by means of the EuroQol-5D and the WOMAC ques-
tionnaires to assess their individual benefit due to
TKA and the subsequent inpatient rehabilitation. Both
questionnaires’ benefit estimates were transformed
into the number of gained quality adjusted life years
[QALYs]. Total direct cost estimates for the overall
care were based on German DRG and rehabilitation
cost rates [ᾬ]. The primary clinical endpoint of the in-
vestigation was the individual number of QALYs
gained by TKA based on the WOMAC interview; the
primary health economic endpoint was the marginal
cost effectiveness ratio (MCER) relating the costs to
the associated gain in quality of life [ᾬ/QALY].
Results: Total direct costs for the overall procedure
were estimed 9549 ᾬ in median. The WOMAC based
interview revealed an overall gain of 4.59 QALYs (in-
terquartile range 2.39 – 6.21 QALYs), resulting in mar-
ginal costs of 1795 ᾬ/QALY (1488 – 3288 ᾬ/QALY).
The corresponding EuroQol based estimates were
2.93 QALYs (1.75 – 5.59 QALYs) and 3063 ᾬ/QALY
(1613 – 5291 ᾬ/QALY). Logistic regression modelling
identified the patients’ age as the primary determinant
of cost effectiveness (Likelihood Ratio p = 0.006): pa-
tients younger than 60 years showed a median gain of
6.45 QALYs and median marginal costs of 1463
ᾬ/QALY, patients between 60 – 70 years 5.47 QALYs
and 1744 ᾬ/QALY, patients older than 70 years 2.76
QALYs and 3186 ᾬ/QALY.
Conclusion: TKA was proven to be cost effective from
a health care insurer’s perspective, although its margin-
al costs notably increased with increasing age. Note,
however, that this age-related gradient in marginal cost
effectiveness is of comparable order as the changes in
cost effectiveness due to variation of the underlying
assessment instrument.
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outcome, quality of life, cost effectiveness
INTRODUCTION
Recent demographic changes in Western Europe im-
ply an increasing demand for health care procedures in
the elderly and thereby increasing ressource allocation
by health care insurers. However, bearing limitations
of the insurers’ total budgets in mind, ressource allo-
cation decisions cannot be exclusively based on clinical
rationales, but must also involve economic aspects
[19]. As a compromising consequence, both the clini-
cal effectiveness and the financial investment of a
medical treatment must be considered simultaneously
to derive a funding decision. The marginal and incre-
mental cost effectiveness ratio concept [14] has been
proven to provide quantitative allocation rationales in
this setting, which allow for both easy interpretation
and direct comparison with treatment alternatives: The
cost effectiveness ratio relates the costs of a treatment
to its benefit from a patient’s perspective, mostly esti-
mated in terms of monetary units per gained quality
adjusted life year (QALY). Estimation of the treat-
ment’s effectiveness in terms of QALYs allows for a
patient-related benefit interpretation as well as for
comparison of its cost effectiveness estimate with the
corresponding health economic characteristic of alter-
native treatments. In particular, the estimation of a
treatment’s cost effectiveness enables health care in-
surers to evaluate its patient-related benefit in compar-
ison to other treatments, which already underwent this
decision process for refunding. Note, in addition, that
such health economic treatment characteristics cannot
only be derived for a treatment procedure in general,
but also allow for patient-specific funding recommen-
dations: estimation of the treatment’s cost effective-
ness among patient sub samples (for example by strati-
76
Eur J Med Res (2009) 14: 76-84 ﾩ I. Holzapfel Publishers 2009
CLINICAL BENEFIT AND COST EFFECTIVENESS OF TOTAL KNEE
ARTHROPLASTY IN THE OLDER PATIENT
F. Krummenauer1, C. Wolf1, K.-P. G￼nther2, S. Kirschner2
1Clinical Epidemiology and Health Economy Unit (Head of the unit: Prof. Dr. F. Krummenauer),
2Department of Orthopedic Surgery (Head of the department: Prof. Dr. K.-P. G￼nther),
University Hospital Carl Gustav Carus, Medical Falculty of the Technical University of Dresden, Germany
6. Krummenauer:Umbruchvorlage  03.02.2009  12:03 Uhr  Seite 76fication of the cost effectiveness estimate for age or
working status): These sub sample estimates will char-
acterize the treatment’s cost / benefit relation in more
detail and thereby may identify patient groups with a
more promising (and therefore fundable) cost / bene-
fit relation, as it would have been assumed for the
overall treatment. Therefore the concept of marginal
and incremental cost effectiveness evaluation finds in-
creasing acceptance and application among both clini-
cians and health economists. By providing a quantita-
tive and therefore transparent rationale in ressource al-
location discussions, its particular value in the need for
health economic evaluation of treatment concepts for
older patients is obvious.
Orthopedic surgery is pretty concerned with the
treatment of the older patient, since the demand for
total hip and knee arthroplasty is catalyzed by both de-
mographic changes and availability of effective and
safe treatment procedures. In particular, total knee
arthroplasty (TKA) presents a treatment offer to the
older patient, who often suffers from a severe loss in
quality of life due to gonarthrosis, but also from prog-
nostically relevant comorbidity. Therefore a direct cost
assessment of TKA based on diagnose related groups
(DRGs) will result in a rather cost-intensive reim-
bursement for health care insurers. Accordingly, the
German DRG rate for unilateral TKA amounts to
7500 ᾬ plus the direct costs for postoperative rehabili-
tation, which at least amount to additional 2000 ᾬ. On
the other hand, TKA has been proven to be effective
from the patients’ perspective concerning regain of
both function and quality of life. Whether the amount
of this patient benefit is associated with the individual
patients’ sociodemographic characteristics, however, is
a matter of sensitive discussion [4, 16].
Bearing recent demographic changes in Western
Europe and the increasing limitations of financial
ressources in Western health care systems in mind, this
investigation was implemented to investigate the order
and determinants of the cost effectiveness of TKA in
the elderly.
PATIENTS AND METHODS
The primary intention of this investigation was to de-
rive an estimate for the cost effectiveness of TKA un-
der stratification of putative (multivariate) outcome
determinants such as age, gender or occupational
state. Therefore a prospective patient-based investiga-
tion with the aim of estimating the cost effectiveness
among the patients under observation was implement-
ed instead of performing a Markov decision analysis
based on meta analysis estimates.
STUDY DESIGN AND PATIENT CHARACTERISTICS
This prospective cost effectiveness investigation com-
prised individual data of patients, who underwent uni-
lateral TKA at the authors’ University Hospital in
2006. A total of 65 patients with the clinical indication
for TKA were enrolled consecutively and asked for
participation in this prospective health economic trial.
After written informed consent patients underwent a
written interview by means of the WOMAC and the
EuroQ(u)ol-5D questionnaire one week before
surgery. The interviews were coordinated by a study
nurse, who offered assistance to the interview if re-
quired. Furthermore the study subjects were invited
for a three months recall to undergo the same inter-
view. This study design was positively rated by the lo-
cal Independent Ethics Committee by June 25th 2005.
The 65 patients (60% females) spent a median dura-
tion of 9 days in hospital. They showed a median age
of 66 years (interquartile range 61 – 74 years, range 45
– 78 years); 31% of patients were older than 70 years,
23% younger than 60 years. Female patients (39% old-
er than 70 years at the day of surgery) showed a medi-
an age of 67 years versus 65 years among male patients
(19% older than 70 years). Among the 65 study pa-
tients, 25% reported to live without a partner or family
members; 12% reported an academic degree. Only 8%
reported their occupational status as “working” or re-
ported to “restart working” after rehabilitation.
OPERATIVE PROCEDURE
The study population consisted of patients with
primary or secondary osteoarthritis of the knee joint
stage 3 or 4 according to Kellgren. The patients were
routinely operated under tourniquet after admission of
perioperative antibiotic prophylaxis in a laminar air-
flow room. Through a straight skin incision and a me-
dial parapatellar approach a cemented Natural Knee II
(Fa. Zimmer, Germany) total knee arthroplasty with-
out resurfacing of the patella was implanted. Postop-
eratively all patients received a risk adjusted anticoagu-
lation treatment, for example, high risk patients re-
ceived arixtra 1x1 s.c. injection over six weeks. Postop-
eratively all patients were allowed for full weightbear-
ing. After discharge from the hospital the patients
were transferred to a inpatient rehabilitation unit for
additional three weeks.
CLINICAL BENEFIT EVALUATION AND MODEL
ASSUMPTIONS
The primary clinical endpoint of this investigation was
the individual gain in quality of life as assessed by
means of the WOMAC questionnaire: Before and
three months after surgery patients answered the 24
WOMAC items, which were documented in terms of a
five-staged ordinal scale. The 24 items were averaged
and transformed into a utility scale of 0 – 100%, where
the scale maximum 100% indicates the optimum well-
being among each of the 24 items. The intraindividual
difference post – pre of this transformed WOMAC in-
dex was then considered as a surrogate for the patients’
clinical benefit achieved by TKA. This surrogate was
then extrapolated alongside the patients’ theoretical
rest life expectancy, where a Gaussian life expectancy
distribution was assumed with mean expectancy of 85
years for women and 80 years for men (both underly-
ing assumed standard deviations of 10 years). Based on
this model assumption the individual (rest) life ex-
pectancy of a patient was simulated. The WOMAC
based clinical benefit was then assumed to persist over
this patient’s simulated rest life period and proportion-
ally extrapolated over time. To account for time-depen-
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shortly after surgery, the overall benefit estimate was
discounted at an annual discounting rate of 3%. If, for
example, a patient had a simulated rest life expectancy
of 10 years after surgery and reported a 25% increase
in terms of the WOMAC based utility scale, his indi-
vidual crude benefit was estimated as 10 years * 25% =
2.5 quality adjusted life years (QALYs). After discount-
ing at the annual 3% loss rate a net TKA benefit of
2.18 QALYs was then estimated for this patient.
However, since a 10 years revision rate of at least 5 –
10% must be assumed after TKA [10], the above simu-
lation of rest life expectancy also introduced a 10 years
censoring for 5% of the patients by random selection.
This model assumption allowed to also simulate the fact
of loss in quality of life when a revision becomes nec-
essary (and thereby imposes new financial investment).
PRIMARY ENDPOINTS AND TARGET PARAMETERS
The primary clinical endpoint of this investigation was
the individual gain in quality of life as illustrated above
[QALYs], when assessed by means of the WOMAC
questionnaire. The most important secondary end-
points were the underlying WOMAC-based benefit es-
timate [%], the corresponding EuroQuol-based bene-
fit estimate [%] and its quality of life derivate
[QALYs], which was estimated in the same manner as
the WOMAC-based analogue.
The primary economical endpoint were the total di-
rect costs [ᾬ], based on German DRG rates for the ini-
tial TKA and the subsequent indoor rehabilitation. The
latter was deterministically modelled by assumption of
a “flat rate” of 2100 ᾬ (refering to average daily costs
of 100 ᾬ during a three weeks inpatient rehabilitation).
The main target parameter of the cost effectiveness
evaluation was the marginal cost effectiveness ratio
(MCER), which relates the direct costs as assessed by
the primary economical endpoint to the associated pa-
tient benefit as assessed by the primary clinical end-
point [ᾬ/QALY]. Both cost and cost effectiveness esti-
mation were performed from the German compulsory
health care insurer’s perspective.
To briefly illustrate the estimation and interpreta-
tion of the MCER endpoint [14], the following nu-
merical example will be sketched out: If, for example,
a patient’s net benefit was estimated 2.18 QALYs and
the overall direct DRG costs for TKA and subsequent
rehabiliation were calculated 9549 ᾬ, this patient’s mar-
ginal costs were estimated as MCER = 9549 ᾬ / 2.18
QALYs = 4380 ᾬ / QALY. Note, that the above study
design allows for estimation of this MCER parameter
for each of the study subjects; the MCER’s distribu-
tion therefore illustrates heterogeneity in the cost ef-
fectiveness of TKA among sub samples of patients. If
a second patient reports a clinical benefit of 4.50
QALY and underwent the same clinical procedure at
an identical cost level, his individual MCER is estimat-
ed 2122 ᾬ / QALY and therefore obviously indicates a
better individual cost / benefit relation as obtained for
the previous patient. For the sake of illustration of
these MCER estimates the marginal costs of monofo-
cal cataract surgery may be mentioned, which were es-
timated 1916 ᾬ / QALY [14]. At least the second of
the above model patients would therefore illustrate a
comparable cost effectiveness of cataract and TKA
surgery (and thereby motivate corresponding funding
recommendation).
The following will introduce an exploratory cut-
point of 2000 ᾬ / QALY such as motivated by the
marginal cost effectiveness order of monofocal
cataract surgery [14], which is undoubted to be fully
refundable by health care insure insurers.
STATISTICALANALYSIS
The distributions of continuous endpoints such as the
primary clinical endpoint and the MCER were de-
scribed by medians and quartiles (graphically on non-
parametric box plots, accordingly) to take account for
possible statistical outliers. The description of cate-
gorical endpoints was based on absolute and appropri-
ate relative frequencies. These methods were applied
to the overall sample as well as to sub samples. Intrain-
dividual comparisons were based on the description of
difference distributions for continuous endpoints and
on total frequencies in contingency tables for categori-
cal endpoints.
The significance evaluation of intraindividual
changes in continuous endpoints was based on pair-
wise sign tests, in categorical endpoints on pairwise
McNemar tests. Sub sample comparisons were based
on pairwise Wilcoxon two sample tests and Kruskal/
Wallis multi sample tests for continuous and on pair-
wise Fisher tests for categorical endpoints. Results of
these tests were summarized in terms of p-values. Due
to the rather exploratory character of the sub sample
comparisons, these p-values were not formally adjusted
for multiplicity. A p-value < 0.05 therefore indicates lo-
cally significant sub sample differences.
A multivariate re-analysis of the cost effectiveness
data was based on categorization of the primary end-
point: TKA treatment was considered to be individual-
ly cost effective, if the underlying MCER was estimat-
ed ≤ 2000 ᾬ / QALY (see section 2.4). This explorato-
ry endpoint allowed for multiple logistic regression
modelling of simultaneous cost effectiveness determi-
nants like age, gender, working and family state. Logis-
tic regression modelling was performed by means of
Likelihood Ratio tests (foreward selection at a local
5% significance level).
All numerical and graphical evaluations were based
on the software SPSSﾮ (release 12.0 for Windowsﾮ).
SENSITIVITY ANALYSIS
The results of a cost effectiveness evaluation crucially
depend on the validity and precision of the underlying
input data: Note that, for example, the model assump-
tions on rest life expectancy of patients (85 years for
female and 80 years for male patients) or on survival of
prosthesis (loss after ten years in 5% of the patients)
can imply bias into the overall MCER estimation.
Therefore a deterministic variation of such input para-
meters and model assumptions was introduced to sim-
ulate their possible imprecision and the resulting im-
pact on the MCER estimate: In the above setting the
model parameter on patient life expectancy, which was
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and EuroQuol results, was varied deterministically over
ﾱ 5 years according to recent age-stratified age tables
provided by German authorities: The latter indicated a
total life expectancy of 75.59 years for male and 81.34
years for female newborns in Germany. Furthermore
they demonstrate a rest life expectany of 19.51 years
(males) versus 23.72 years (females) for people aged
between 60 – 65 years and of 15.79 years (males) ver-
sus 19.44 years (females) for people aged between 65 –
70 years. The resulting imprecision in the rest life ex-
pectancy estimates was therefore summarized by the
above deterministic assumptions.
The input parameter on prosthesis survival was var-
ied [10] over ﾱ 3 % (thereby ranging from 2 – 8%) and
the “flat rate” assumed for the direct costs of postop-
erative rehabilitation over ﾱ 200 ᾬ per patient (there-
fore ranging between 1900 – 2300 ᾬ).
A second direction of sensitivity analysis consid-
ered the measurement instrument, which was applied
to assess the primary clinical endpoint: whereas the
WOMAC questionnaire rather estimates a semi-func-
tional outcome, which is highly associated with health-
related quality of life, the EuroQuol questionnaire
rather estimates general health-related quality of life.
Both estimates can be considered as patient-related
surrogate endpoints and therefore characterize the
clinical benefit of TKA from the patient’s perspective.
To quantify the assessment instrument’s impact on the
MCER estimate, the EuroQuol based MCER’s distrib-
ution was considered in terms of a sensitivity analysis
for the WOMAC based results.
RESULTS
Both the clinical and the economical primary endpoint
could be evaluated for each of the 65 patients under
investigation. One week before surgery, the overall
sample reported a median WOMAC utility score of
41% (34 – 47%), which hardly varied among age
decades: whereas patients younger than 60 years at the
day of surgery reported a median score of 38%, pa-
tients between 60 – 70 years and patients older than 70
years reported a median score 41%, respectively. Three
months after surgery the overall sample reported a
WOMAC score of 81% (64 – 88%), which varied
among the age decades from 72% over 82 and 81%,
respectively. The corresponding median EuroQuol
score rose from 40% (32 – 54%) before surgery to
70% (65 – 78%) after surgery with a similar age-relat-
ed gradient in favour of the older patients as observed
for the WOMAC based score.
Table 1 summarizes the intraindividual changes in
the underlying 24 WOMAC items and illustrates sub-
stantial and statistically significant improvement for
each aspect under consideration (McNemar p<0.001
for each of the items): the fraction of patients report-
ing subjective improvement three months after surgery
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Table 1. Relative frequencies for self-reported improvement or worsening in the 24 WOMAC questionnaire items three months
after versus one week before TKA.
improvement worsening
pain
when walking on flat ground 78 % 3 %
when walking up / down stairs 82 % 3 %
which discontinuous night sleep 57 % 8 %
in sitting or lying 68 % 10 %
in straight standing 87 % 1 %
stiffness
after first morning wake up 64 % 13 %
after over-day rest 78 % 6 %
difficulties
when stepping down stairs 76 % 5 %
when stepping up stairs 78 % 6 %
in standing up when sitting 79 % 3 %
in straight standing 89 % 3 %
when picking things from floor 76 % 8 %
when walking on flat ground 78 % 2 %
when entering a car or bus 76 % 8 %
when going shopping 76 % 7 %
when putting on socks.etc. 74 % 6 %
when putting off socks etc. 84 % 5 %
in getting out of bed 76 % 8 %
when lying in bed 68 % 3 %
when entering or leaving a bath tub 62 % 0 %
in sitting for a longer time 68 % 7 %
when sitting on the toilet 76 % 8 %
in doing less easy homework 72 % 3 %
in doing easy homework 76 % 5 %
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was reported for items associated with pain symptoms.
CLINICAL BENEFIT EVALUATION
The median intraindividual increase in the WOMAC
score was 38% (25 – 45%, sign test p<0.001), the cor-
responding EuroQuol score increase was estimated
30% (15 – 40%, p = 0.008) in median (Table 2). The
transformation of these score increases into quality
adjusted life years revealed a median benefit of 4.59
QALYs (2.39 – 6.21 QALYs) for the WOMAC score
and of 2.93 QALYs (1.75 – 5.59 QALYs) based on the
EuroQuol questionnaire.
According to the model-associated impact of life
expectancy into QALY calculation, but in contradic-
tion to the above age-related gradient in the postoper-
ative score estimates in favour of the older patients,
the age decades notably varied in both QALY benefit
estimates: Whereas the intraindividual WOMAC score
increase did neither statistically nor clinically signifi-
cantly differ between the three decades under consid-
eration (median increases 34%, 41% and 38%, respec-
tively, pairwise Wilcoxon tests’ p-values between 0.095
and 0.260), a statistically significant age difference was
observed for the QALY estimates: patients older than
70 years reported a median clinical benefit of 2.76
QALYs, whereas patients between 60 – 70 years and
patients younger than 60 years reported median bene-
fits of 5.47 and 6.48 QALYs, respectively (pairwise
Wilcoxon test p-values versus patients older than 70
years < 0.001 for both age groups, respectively). The
same tendency holds for the EuroQuol based benefit
estimates with medians of 1.75 QALYs versus 4.25
and 4.78 QALYs (Wilcoxon p = 0.004 and p<0.001,
respectively).
Table 3 summarizes the results of clinical benefit
estimation under stratification for age, gender and ac-
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Table 2. Medians and quartiles for the distribution of the pre- and postoperative WOMAC index and EuroQuol-5D utility in-
dex [%] in patients undergoing total knee arthroplasty, their respective intraindividual change [%] with p-values derived from
sign tests, the resulting gain in patient quality of life [QALYs] and the marginal cost effectiveness ratio [ᾬ/QALY] from the
health care insurers’ perspective.
Median Q1 – Q3 p(sign test)
WOMAC pre 41 % 34 – 47 %
WOMAC post 81 % 64 – 88 %
WOMAC change 38 % 25 – 45 % p<0.001
EQ-5D pre 40 % 32 – 54%
EQ-5D post 70 % 65 – 78 %
EQ-5D change 30 % 15 – 40 % p = 0.008
WOMAC based gain 4.59 QALYs 2.39 – 6.21 QALYs
EQ-5D based gain 2.93 QALYs 1.75 – 5.59 QALYs
WOMAC based 1795 1588 – 3288
marginal costs ᾬ / QALY ᾬ / QALY
EQ-5D based 3064 1613 – 5291
marginal costs ᾬ / QALY ᾬ / QALY
Table 3. Medians and quartiles for the distribution of the gain in patient quality of life [QALYs] after total knee arthroplasty and
the corresponding marginal cost effectiveness ratio [ᾬ/QALY] from the health insurers’ perspective, stratified for gender, age
and occupational status of patients at the day of surgery.
WOMAC based gain WOMAC based marginal costs EQ-5D based gain EQ-5D based marginal costs
[QALYs] [ᾬQALY] [QALYs] [ᾬ/QALY]
total sample 4.59 1795 2.93 3064
gender
female 3.79 2142 2.93 3260
male 5.61 1660 3.08 2847
age
< 60 years 6.48 1463 4.78 1894
60 – 70 years 5.47 1744 4.25 2093
> 70 years 2.76 3186 1.75 5455
working status
working 6.48 1474 2.45 3908
not working 4.46 1829 2.93 2961
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significant difference in TKA benefit was observed
between patients under recent employment and those
out of employment (work-seeking, drawing a pension
etc.) with a median difference of 6.48 versus 4.46
QALYs (Wilcoxon p = 0.004). Note that the median
difference between these sub samples is of compara-
ble order as already observed for the age sub samples,
when benefit estimation is based on the WOMAC
interview. Regarding the fact, that none of the
patients older than 70 years was still under employ-
ment, the working state gradient must in fact be inter-
preted as being confounded by the age-related gradi-
ent already mentioned above. If, however, QALY cal-
culation is based on the EuroQuol scores, neither a
clinically relevant nor a statistically significant associa-
tion with the patients’ working state is observed (me-
dian benefit estimates 2.45 versus 2.89 QALYs,
Wilcoxon p = 0.522). Note, however, the smaller me-
dian benefit estimate for patients under employment,
which is in contradiction to the WOMAC based re-
sults.
The same tendencies hold for a gender specific
evaluation: Table 3 illustrates a higher TKA benefit for
male patients (5.61 QALYs in median) than for fe-
males (3.79 QALYs in median, Wilcoxon p = 0.002).
Note, however, that the gender samples also differ in
age distribution (see section 2.1) with fractions of
39% (females) versus 19% (males) of patients older
than 70 years at the day of surgery. Therefore the gen-
der-associated difference in benefit estimation must
also be considered as a confounding effect of the
dominating age-related gradient. Again only a slight
sample difference was observed in the EuroQuol
based benefit medians (2.93 QALYs for females versus
3.08 QALYs for males).
COST EFFECTIVENESS EVALUATION
The overall sample demonstrated a median cost effec-
tiveness ratio of 1795 ᾬ / QALY (1588 – 3288 ᾬ /
QALY) when MCER estimation used the WOMAC
utility scores; based on the EuroQuol scores median
marginal costs of 3064 ᾬ / QALY (1613 – 5291 ᾬ /
QALY) were found. A fraction of 53% patients
showed individual marginal costs < 2000 ᾬ / QALYs
based on the WOMAC interview versus 33% based on
the EuroQuol questionnaire.
According to the observations in QALY estimates,
a statistically significant and economically relevant as-
sociation between the MCER and the patients’ age was
observed (Fig.1): based on the WOMAC data, the
marginal costs for patients younger than 60 years were
estimated 1463 ᾬ / QALY, for patients between 60 –
70 years and patients > 70 years 1744 and 3186 ᾬ /
QALY, respectively (Kruskal/Wallis p = 0.001). A sim-
ilar tendency was observed in the EuroQuol based
MCERs (Fig. 2) with respective medians of 1894, 2093
and 5455 ᾬ / QALY (Kruskal/Wallis p<0.001). Table
3 summarizes the MCER estimates among gender, age
and working state sub samples: It illustrates a slightly
better cost / benefit relation for male and for em-
ployed patients than for females and for patients out
of employment, respectively.
MULTIVARIATE ANALYSIS
Logistic regression modelling of the exploratory end-
point “individual MCER < 2000 ᾬ / QALY” con-
firmed the dominating age impact on the cost effec-
tiveness outcome: Whereas neither gender nor work-
ing nor family state were found to be significantly as-
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Fig. 1. Box whisker plots for the distribution of the marginal
costs [ᾬ/QALY] for total knee arthroplasty, based on quality
of life gain assessment by means of the WOMAC arthrosis
index and stratified for the patients’ age decade at the day of
surgery
Fig. 2. Box whisker plots for the distribution of the marginal
costs [ᾬ/QALY] for total knee arthroplasty, based on quality
of life gain assessment by means of the EuroQuol-5D health
utility index and stratified for the patients’ age decade at the
day of surgery
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hood Ratio p = 0.201, p = 0.475 and p = 0.364, re-
spectively), the statistical signficance of the age-related
gradient was strictly reproduced (Likelihood Ratio p =
0.006). As already observed by univariate analysis, pa-
tients between 60 – 70 years and patients younger than
60 years significantly contrasted from patients older
then 70 years (Likelihood Ratio p = 0.012 and p =
0.002, respectively).
SENSITIVITY ANALYSIS
Sections 3.1 and 3.2 already indicated the assessment
instruments’ substantial impact on the MCER out-
come: In general clinical benefit and cost effectiveness
estimates turned out relevantly and significantly more
conservative when being based on the EuroQuol in-
stead of the WOMAC questionnaire (McNemar p =
0.017). In terms of the exploratory endpoint “individ-
ual MCER < 2000 ᾬ / QALY”, only 60% of the over-
all sample are concordantly rated “cost effective” or
“not cost effective” by the respective individual
WOMAC and EuroQuol based MCER estimates.
Bearing the MCER distribution’s medians 1795 and
3064 ᾬ / QALY in mind, an interquartile sensitivity
range of 1588 – 5291 ᾬ / QALY must be assumed
due to changes in the assessment instrument.
Note that this imprecision is in fact due to the instru-
ment at hand and not an epi-phenomenon of the cho-
sen strategy for QALY calculation (section 2.1):
The primary basis of the QALY estimates are the
WOMAC and EuroQuol based utility scores (as
estimated in terms of the respective intraindividual
score changes). The latter differed significantly in the
overall sample (sign test p = 0.006) with a median dif-
ference of 9% (11% for females and 6% for males in
median).
In comparison to the numerical impact of the un-
derlying assessment instrument, the deterministic
variation of the model parameters mentioned in sec-
tion 2.6 can be regarded negligible: variation of the
expectable prosthesis failure rate (5% ﾱ 3%) implied a
variation of 1755 – 1812 ᾬ / QALY for the initial
WOMAC based MCER estimate 1795 ᾬ / QALY, the
variation of the patients’ individual life expectancy
(85 ﾱ 5 and 80 ﾱ 5 years) a corresponding range of
1580 – 1905 ᾬ / QALY. If the individual life ex-
pectancies’ distribution was simulated accoring to the
age-stratified rest life expectancy estimates outlined in
section 2.5, a rather similar range of 1618 – 1822 ᾬ /
QALY was observed for the MCER estimate. Howev-
er, the initially observed statistical signficance of the
age-related MCER gradient was strictly reproduced
(Likelihood Ratio p = 0.015), where patients between
60 – 70 years and patients younger than 60 years sig-
nificantly contrasted from patients older then 70
years.
Finally the variation of the assumed cost rate for
postoperative rehabilitation (2100 ᾬ ﾱ 200 ᾬ) resulted
in a median MCER range of 1712 – 1878 ᾬ / QALY.
None of these deterministic sensitivity analyses re-
vealed a median MCER larger than 2000 ᾬ / QALY,
which implies encouraging robustness of the MCER
estimation strategy chosen for the primary analysis.
DISCUSSION
This investigation intended to quantify the clinical ben-
efit (in terms of quality of life improvement) and the
individual cost / benefit relation of total knee arthro-
plasty from a health insurer’s perspective. Primary in-
tention of the cost effectiveness evaluation was to de-
rive quantitative cost effectiveness characteristics for
TKA in Western European patients and thereby to
provide rationales for recent discussions on ressource
allocation to Orthopedic surgery in Western European
health care systems. The above data revealed a margin-
al cost effectiveness ratio of about 1800 ᾬ / QALY and
therefore demonstrates unilateral TKA to be as cost ef-
fective as for example monofocal cataract surgery with
an MCER of about 1900 ᾬ / QALY. Nevertheless, an
economically relevant and statistically significant asso-
ciation of the TKA cost effectiveness outcome with
the patients’ age at surgery was observed: Whereas
TKA in patients < 60 years was found to be thorough-
ly cost effective, the procedure must be considered
rather more expensive for patients older than 70 years
regarding a median cost effectiness ratio of over 3000
ᾬ / QALY. It must be emphasized that this age-related
gradient in cost effectiveness is strictly a surrogate of
the assumption of smaller rest life expectancy for
those patients (which means a smaller benefit time af-
ter surgery) as compared to younger patients: The
crude clinical benefit was found merely comparable
among these decades with median WOMAC score in-
creases of about 34 – 41% and even a slightly higher
benefit reported by older patients. After correction of
this benefit estimate for the expectable life time, how-
ever, a statistically significant age gradient was ob-
served in the QALY and MCER estimates.
The authors wish to emphasize that their personal
interpretation of this result is the confirmation of
funding TKA for patients older than 70 years! Note
that in this investigation patients of this decade
showed an age range between 70 and 78 years – even
under maximum formal interpretation of the model
assumptions on rest life expectancy (80 – 85 years, see
section 2.1) each patient in this investigation is there-
fore complimented with a minimum rest life expectany
of at least two years. Bearing the fact in mind that the
indication and decision for TKA is rather an “ultima
ratio” offer to patients suffering from immobility and
continuous pain, to prolong this painful state for over
a minimum of two life years cannot be justified from
an ethical perspective.
METHODOLOGICAL ASPECTS
The cost effectiveness of TKA has yet been widely
discussed and quantified [3, 15, 16] in patient samples
recruited in the U.S.A. and the U.K. as well as in Scan-
dinavia. Its overall performance is accepted to be cost
effective and may be slightly superior to that of total
hip arthroplasty [1, 2, 3, 7, 8, 11, 16]. In particular the
observation of inferior cost effectiveness profiles in
patients older than 70 years is a well-accepted fact [4,
16]. Recent investigations rather concentrate on possi-
bilities of improvement in the cost effectiveness of
TKA by, for example, introducing the advantages of
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optimization, by making use of computer assisted
surgery tools [9] or less invasive surgery [17, 18], or by
improving patient compliance by providing oral and
written information as well as physiotherapeutic exer-
cises before TKA.
However, a lot of this recently published informa-
tion is – according to the actual research hypothesis at
hand or due to the cost reimbursement strategies on
site – rather based on the health care provider’s per-
spective instead of the health care insurer’s. Further-
more, some authors do not provide appropriate out-
come measures in terms of utility socres or quality ad-
justed life years, which enable the comparison of TKA
cost effectiveness characteristics with those of concur-
ring treatment offers (and thereby allow health care in-
surers to apply the cost effectiveness information in
local ressource allocation discussions). As a conse-
quence, only few published data allows for direct and
quantitative comparison of its cost effectiveness char-
acteristics with the above MCER estimates, which
were primarily derived for interpretation in the setting
of Western European health care systems.
Rissanen et al. report a standardized utility score in-
crease of 9% in patients younger than 60 years, of 5%
in patients aged between 60 – 70 years and 2% for old-
er patients. If median ages of 55, 65 and 75 years are
assumed for these sub samples, a crude extrapolation
for a median life expectancy of 85 years would result
in respective crude benefit estimates of 2.70 QALYs,
1.00 QALYs and 0.2 QALYs respectively. Wherease
the age-related gradient observed by Rissanen et al. is
strictly reproduced by the German patient data pre-
sented in the above, the absolute order of clinical ben-
efit estimates based on the latter crucially differs from
the Scandinavian benefit characteristics. Since Rissa-
nen et al. reported overall treatment costs of about
10.000 ᾬ per patient with a 15% cost increase for pa-
tients older than 70 years, the resulting MCER esti-
mates would dramatically exceed the sensitivity range
< 5.500 ᾬ / QALY as obtained here.
Two main putative reasons may have induced these
deviations: Wherease the WOMAC index used in the
above investigation is rather a surrogate of clinical
function in daily life [13], and therefore its postopera-
tive increase only presents a proxy estimate of TKA
utility, the 15D questionnaire results reported by Ris-
sanen et al. more directly estimate changes in health-
related quality of life. To obtain comparability with
this approach the EuroQuol-5D [5] questionnaire was
used in the recent setting, which in fact resulted in sig-
nificantly smaller clinical benefit estimates. The latter,
however, were still found much larger than the ones
reported by Rissanen et al. [16]. A second direction of
explanation for the clinically relevant difference in the
benefit estimates may draw attention to differences in
the underlying study designs: Whereas the above Ger-
man data was acquired three months after surgery, the
postoperative Scandinavian outcome assessment took
place 24 months after TKA. It can only be hypothe-
sized, whether a three months recall period may have
resulted in somewhat optimistically biased results due
to a persisting benefit from inpatient rehabilitation
care, but which would soon have turned more conser-
vative at an additional six months recall. Since the
process of recovering and continuous improvement
after TKA must be assumed to last for at least one
year, these several concurring possibly conservative or
liberal biases complicate the direct comparison of its
three months and two years outcome.
In particular, Rissanen’s two years follow-up design
directly allows for the observation of short-term com-
plications and the resulting re-treatment costs and out-
come: In the above cohort, no revision to any reasons
was observed within three months after initial TKA,
which would have notably reduced the respective pa-
tients’ indicidual cost effectiveness estimate [6]. Two
directly postoperative complications due to comorbid-
ity were observed, but no additional costs were ob-
served for their immediate re-treatment (as induced by
the German DRG system, which does not consider
additional real costs for complication treatment within
30 days after the initial TKA).
Both design deviations from the Scandinavian regis-
ter based investigation may have imposed a liberal bias
on the WOMAC and EuroQuol outcome estimates.
Therefore further recalls of the above patient cohort
are necessary to reproduce or at least robustify the
TKA outcome estimates found here.
CONCLUSION
A three months recall after TKA revealed an overall
cost effectiveness ratio of 1795 ᾬ / QALY, which
showed a statistically significant and econimically rele-
vant association with the patients’ age at the time of
surgery. Patients older than 70 years showed a similar
WOMAC based clinical benefit as found for younger
patients, but a more pessimistic QALY based cost ef-
fectiveness characteristic. The data at hand do not
contradict TKA in patients older than 70 years.
Comment: The content of this manuscript was presented dur-
ing the 2007 annual meeting of the German Society for Or-
thopedics and Orthopedic Surgery (DGOOC) in Berlin, as
well as during the 2007 annual meeting of the German Soci-
ety for Medical Informatics, Biometry and Epidemiology
(GMDS) in Augsburg.
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